Genomic structure and functional characterization of the human ADAM10 promoter
Abstract
The ADAM10 gene encodes a membrane-bound disintegrin-metalloproteinase, which, after overexpression in an Alzheimer disease (AD) mouse model, prevents amyloid pathology and improves long-term potentiation and memory. Because enhancing ADAM10 expression appears to be a reasonable approach for treatment of AD, we functionally analyzed the ADAM10 gene. Both human and mouse ADAM10 genes comprise approximately 160 kbp, are composed of 16 exons, and are evolutionarily highly conserved within 500 bp upstream of either translation initiation site. By using luciferase reporter assays, we demonstrate that nucleotides -2179 to -1 upstream of the human ADAM10 translation initiation site represent a functional TATA-less promoter. Within this region we identified and examined several single nucleotide polymorphisms, but did not detect significant differences in their appearance between AD and nondemented control subjects. By deletion analysis, site-directed mutagenesis, transcription factor overexpression and electrophoretic mobility shift assays, we identified nucleotides -508 to -300 as the core promoter and found Sp1, USF, and retinoic acid-responsive elements to modulate its activity. Finally, we identified vitamin A acid (RA) as an inducer of human ADAM10 promoter activity. This finding suggests that pharmacologic targeting of RA receptors may increase the expression of the alpha-secretase ADAM10 with beneficial effects on AD pathology.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
ADAM10 transcript expression is regulated by retinoic acid.
“ADAM10 transcript expression is regulated by retinoic acid (13)”
From GDE2-RECK controls ADAM10 α-secretase–mediated cleavage of amyloid precursor protein (2021) · cites this paper as [13]
Cited by
Sorted by citations
Retinoic acid in the development, regeneration and maintenance of the nervous system
Maden, M. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2212 · Cited by 896 · see citing works
Towards Retinoid Therapy for Alzheimers Disease
Shudo, K., Fukasawa, H., Nakagomi, M., & Yamagata, N. (2009) · Current Alzheimer Research · doi:10.2174/156720509788486581 · Cited by 91 · see citing works
Partial loss of endothelial nitric oxide leads to increased cerebrovascular beta amyloid
Austin, S. A., & Katusic, Z. S. (2020) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x18822474 · Cited by 52 · see citing works
Retinoids for treatment of Alzheimer’s disease
Lerner, A. J., Gustaw‐Rothenberg, K., Smyth, S., & Casadesus, G. (2012) · BioFactors · doi:10.1002/biof.196 · Cited by 44 · see citing works
GDE2-RECK controls ADAM10 α-secretase–mediated cleavage of amyloid precursor protein
Nakamura, M., Li, Y., Choi, B.-R., Matas-Rico, E., Troncoso, J., Takahashi, C., & Sockanathan, S. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abe6178 · Cited by 38 · see citing works
- Authors
- Prinzen, C., Müller, U., Endres, K., Fahrenholz, F., & Postina, R.
- Affiliations
- Johannes Gutenberg University Mainz (DE)
- Justus-Liebig-Universität Gießen (DE)
- Venue
- The FASEB Journal
- Publisher
- Wiley
- Published
- 2005-06-21
- Volume
- 19
- Issue
- 11
- Pages
- 1522-1524
- ISSN
- 0892-6638 (ISSN-L)
- 1530-6860
- OpenAlex
- W2156246185
- Cited by
- 131
- References
- 0
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 3 · 2023: 5 · 2022: 3 · 2021: 3 · 2020: 5 · 2019: 6 · 2018: 8 · 2017: 6 · 2016: 9 · 2015: 9 · 2014: 4 · 2013: 7 · 2012: 7
- FWCI
- 3.40
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The FASEB Journal (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Deutsche Forschungsgemeinschaft
- Topics
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Protease and Inhibitor Mechanisms
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- ADAM10, promoter structure, Alzheimer's disease, TATA-less promoter, core promoter, Sp1, USF, retinoic acid responsive element, retinoic acid, single nucleotide polymorphisms, transcription factor binding sites, alpha-secretase, amyloid pathology, gene expression regulation
- MeSH terms
- ADAM10 Protein, Alzheimer Disease, Animals, Cell Line, Exons, Humans, Introns, Membrane Proteins, Promoter Regions, Genetic, Tretinoin, Mutagenesis, Site-Directed, Open Reading Frames, Conserved Sequence, Expressed Sequence Tags, Polymorphism, Single Nucleotide, 5' Flanking Region, Mice, ADAM Proteins, Amyloid Precursor Protein Secretases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review